Clinical Trials on Mullerian Aplasia

Total 4937 results

AGO Study Group
Essex Pharma GmbH; MedServ. GmbH, Wiesbaden

Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Cervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian Tumours

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Roswell Park Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Completed

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
The Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...

Terminated

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Millennium... and other collaborators

Active, not recruiting

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
NYU Langone Health
National Institute on Deafness and Other Communication Disorders (NIDCD)

Recruiting

Using tDCS in Speech-based Stroke Rehabilitation

Apraxia of Speech

United States
Alcon Research

Recruiting

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

Presbyopia | Astigmatism | Aphakia

United States, Puerto Rico
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Oncolytics Biotech

Completed

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Yvonne Efebera
Bristol-Myers Squibb; National Cancer Institute (NCI); American Cancer Society...

Terminated

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia

Hepatitis-Associated Aplastic Anemia

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Shahid Beheshti University

Completed

High-fat Yogurt and Plasma Lipids Profile

Plasma Lipid Profile

Iran, Islamic Republic of
Aibin Liang，MD，Ph.D.
CARsgen Therapeutics Co., Ltd.

Recruiting

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in Relapse

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Blueprint Medicines Corporation

Recruiting

(VELA) Study of BLU-222 in Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Carcinosarcoma | Advanced Solid Tumors | Endometrial Cancer | Esophageal Adenocarcinoma | HER2-negative Breast Cancer | CCNE1 Amplification | HR+ Breast Cancer

United States, Italy, United Kingdom
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (P204)

Ovarian Cancer | Carcinosarcoma | Endometrial Cancer | Uterine Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Endometrial Cancer | Endometrial Carcinoma | Endometrial Carcinosarcoma | Endometrial Cancer Recurrent | Endometrial Carcinoma, Recurrent

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Congenital Amegakaryocytic Thrombocytopenia | Severe Congenital Neutropenia | Diamond-blackfan Anemia

United States
Anhui Medical University

Recruiting

High Definition Transcranial Alternating Current Stimulation (HD-tACS) for Post-stroke Aphasia

Functional Magnetic Resonance Imaging | Post-stroke Aphasia | Transcranial Alternating Current Stimulation

China
Becton, Dickinson and Company

Completed

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Plasma Cell Disorder

Switzerland, Spain, United Kingdom, United States, Portugal
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Autoimmune Diseases | Hodgkin Lymphoma | Hematologic Malignancies | Acute Lymphoblastic Leukemia (ALL) | Non-hodgkin Lymphoma | Severe Aplastic Anemia | Inherited Disorders of Metabolism | Inherited Abnormalities of Platelets | Histiocytic Disorders | Acute Myelogenous Leukemia (AML or ANLL) | Other Acute... and other conditions

United States
Alcon Research

Recruiting

Evaluation of Long-term Safety and Performance of PanOptix Intraocular Lens (IOLs)

Presbyopia | Astigmatism | Aphakia

Spain
Alcon Research

Completed

Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs

Presbyopia | Astigmatism | Aphakia

United States, Puerto Rico
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

Severe Aplastic Anemia (SAA) | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)

United States
RxSight, Inc.

Completed

Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism

Cataract | Aphakia

Mexico
RxSight, Inc.

Completed

A Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

Cataract | Aphakia

United States
Second Affiliated Hospital, School of Medicine,...

Completed

Clinical Observation of the Transscleral Suture Fixation of Posterior Chamber Intraocular Lens in Eyes With Inadequate Capsule Support

Aphakia | Absence of Capsule Support

China
Alcon Research

Completed

Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens

Corneal Astigmatism | Aphakia

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain Only

United States
National Cancer Institute (NCI)

Withdrawn

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | t(11;14) Negative

Clinical Trials on Mullerian Aplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations